Therapeutic effect of repetitive transcranial magnetic stimulation in Parkinson's disease: Analysis of [11C] raclopride PET study

Repetitive transcranial magnetic stimulation (rTMS) has been used as a potential therapeutic tool in Parkinson's disease (PD). However, the therapeutic value and/or the placebo effect of rTMS on PD remain to be elucidated. To investigate the therapeutic value and/or placebo effect of rTMS in PD...

Full description

Saved in:
Bibliographic Details
Published in:Movement disorders 2008-01, Vol.23 (2), p.207-211
Main Authors: Kim, Ji Youn, Chung, Eun Joo, Lee, Won Yong, Shin, Hee Young, Lee, Gyeong Han, Choe, Yearn-Seong, Choi, Yong, Kim, Byeong Joon
Format: Article
Language:English
Subjects:
[11C] raclopride PET
Adult
Aged
Biological and medical sciences
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Electric Stimulation - methods
Female
Humans
Male
Medical sciences
Middle Aged
Neurology
Parkinson Disease - diagnostic imaging
Parkinson Disease - therapy
Parkinson's disease
placebo effect
Positron-Emission Tomography
Raclopride - metabolism
repetitive transcranial magnetic stimulation
Severity of Illness Index
Transcranial Magnetic Stimulation - methods
Tritium
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Repetitive transcranial magnetic stimulation (rTMS) has been used as a potential therapeutic tool in Parkinson's disease (PD). However, the therapeutic value and/or the placebo effect of rTMS on PD remain to be elucidated. To investigate the therapeutic value and/or placebo effect of rTMS in PD, we compared the motor section of unified PD rating scale (UPDRS III) and the amount of extracellular dopamine concentration using [11C] raclopride PET before and after two sessions of rTMS in 9 PD patients. During a consecutive 2 days while off‐medication, two series of 15 trains of 5 Hz‐frequency rTMS (intensity, 90% of the resting motor threshold) were applied to the hand area of more severely symptomatic motor cortex (MC). After unilateral rTMS of MC, mean raclopride binding potentials (BPs) were reduced not only in putaminal and caudate areas on the stimulated side (−4.9% and −6.5%, respectively) (P > 0.05) but also in putaminal and caudate areas of nonstimulated hemispheres (−6.6%, P > 0.05 and −12.1%, P = 0.049, respectively). UPDRS III scores were significantly decreased (35.0 ± 14.1 to 32.0 ± 13.4, P = 0.049). A reduction of raclopride BP in nonstimulated ventral striatum by unilateral rTMS supports the placebo response during rTMS. © 2007 Movement Disorder Society
ISSN:0885-3185
1531-8257
DOI:10.1002/mds.21787